Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
Next >
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
June 25, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
June 17, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
June 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
June 12, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
June 10, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
June 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
June 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
May 27, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
May 23, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
May 22, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
May 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
May 01, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
April 29, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Q1 2024 results
April 25, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
April 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
April 11, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
April 05, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
April 05, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
April 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
March 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
March 18, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
March 13, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
February 23, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
February 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
February 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
February 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Full year and Q4 2023 Financial Results
February 08, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.